サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1544105

着床前遺伝子診断（PGD）の世界市場

Preimplantation Genetic Diagnosis (PGD)

出版日
ページ情報
英文 173 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
着床前遺伝子診断（PGD）の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

着床前遺伝子診断（PGD）の世界市場は2030年までに1億6,040万米ドルに達する見込み

2023年に1億1,490万米ドルと推定される着床前遺伝子診断（PGD）の世界市場は、2030年には1億6,040万米ドルに達すると予測され、分析期間2023～2030年のCAGRは4.9%で成長すると予測されます。本レポートで分析したセグメントの1つである染色体異常は、CAGR 4.2％を記録し、分析期間終了までに3,360万米ドルに達すると予測されます。異数性セグメントの成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は3,060万米ドルと推定、中国はCAGR7.2%で成長すると予測

米国の着床前遺伝子診断（PGD）市場は、2023年に3,060万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 7.2%で推移し、2030年までに3,460万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と4.3%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の着床前遺伝子診断（PGD）市場- 主要動向と促進要因まとめ

着床前遺伝子診断（PGD）：遺伝子の健康を守る

着床前遺伝子診断（PGD）は体外受精（IVF）と併用される特殊な方法で、子宮に移植する前に胚の遺伝子異常をスクリーニングします。この技術により、遺伝性疾患や染色体異常の既往歴のあるカップルは、子孫に遺伝するリスクを減らすことができます。PGDでは、通常受精後3～5日目に、発育中の胚から1つ以上の細胞を生検し、その後遺伝子解析を行い、特定の突然変異や染色体異常を検出します。遺伝子異常のない胚のみが着床用に選択されるため、健康な妊娠の可能性が高まり、遺伝性疾患のリスクを減らすことができます。PGDは、嚢胞性線維症、ハンチントン病、鎌状赤血球貧血などの遺伝性疾患の保因者であるカップルにとって、生殖プロセスにおいてさらなる保証を提供するため、特に価値があります。

技術の進歩は着床前遺伝子診断（PGD）をどのように向上させているか？

技術の進歩は、着床前遺伝子診断（PGD）の精度、信頼性、範囲を大幅に改善しました。次世代シーケンサー（NGS）の登場は、全ゲノムの包括的な解析を可能にすることでPGDに革命をもたらし、より広範な遺伝子異常をより正確に検出することを可能にしました。この技術はまた、遺伝子解析に要する時間を短縮し、体外受精プロセスにおける迅速な意思決定を可能にしています。5日目胚の体外生検のような、より洗練された生検技術の開発は、PGDの安全性と有効性を高め、胚への危害のリスクを最小化すると同時に、より大きく代表的な分析用サンプルを提供しています。さらに、バイオインフォマティクスとデータ解析の進歩は、遺伝子データの解釈を強化し、胚の遺伝的健康についてのより正確で詳細な洞察を提供しています。このような技術的な向上はPGDの応用範囲を広げ、将来の世代の遺伝的健康を保証するためのより強力なツールとなっています。

着床前遺伝子診断（PGD）の主な用途と利点は何ですか？

着床前遺伝子診断（PGD）は様々な生殖の場面で使用され、健康な妊娠の可能性を高め、遺伝的障害のリスクを軽減する多くの利点を提供します。両親の一方または両方が既知の遺伝子変異の保因者である場合、PGDによって変異を持たない胚を選択することができ、子供に遺伝するリスクを大幅に減らすことができます。PGDはまた、妊娠の成功の可能性が低い染色体異常を持つ胚を同定するのに役立ちます。さらに、PGDは体外受精を受ける高齢の女性にとって、ダウン症のような加齢に関連した染色体異常をスクリーニングすることができ、健康な妊娠の可能性を高めることができるため、貴重なものです。PGDの主な利点は、遺伝性疾患のリスクを軽減し、体外受精の成功率を高め、親になる人に安心感を与えることができることです。遺伝的に健康な胚の選択を可能にすることで、PGDは生殖プロセスを強化し、将来の世代の長期的な健康に貢献します。

着床前遺伝子診断（PGD）市場の成長を促進する要因は？

着床前遺伝子診断（PGD）市場の成長は、いくつかの要因によって牽引されています。遺伝性疾患の有病率の増加や、生殖医療における遺伝子スクリーニングの利点に対する意識の高まりは、重要な促進要因です。また、PGDの精度、安全性、アクセス性を向上させる技術の進歩も市場成長を後押ししています。特に高齢の女性や遺伝性疾患の既往歴のある夫婦の間で体外受精の需要が高まっていることが、PGDの採用をさらに後押ししています。さらに、PGDプロセスを通じてカップルを導く遺伝カウンセリング・サービスの拡大も市場成長に寄与しています。高度な遺伝子検査技術の利用可能性の増大と個別化医療への注目の高まりが、市場をさらに牽引しています。これらの要因は、生殖遺伝学における継続的な技術革新と相まって、PGD市場の持続的成長を後押ししています。

調査対象企業の例（注目の46社）

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings（LabCorp）
  • Natera, Inc.
  • PerkinElmer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP14183

Global Preimplantation Genetic Diagnosis (PGD) Market to Reach US$160.4 Million by 2030

The global market for Preimplantation Genetic Diagnosis (PGD) estimated at US$114.9 Million in the year 2023, is expected to reach US$160.4 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Chromosomal Abnormalities, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$33.6 Million by the end of the analysis period. Growth in the Aneuploidy segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.6 Million While China is Forecast to Grow at 7.2% CAGR

The Preimplantation Genetic Diagnosis (PGD) market in the U.S. is estimated at US$30.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$34.6 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Preimplantation Genetic Diagnosis (PGD) Market - Key Trends and Drivers Summarized

Preimplantation Genetic Diagnosis (PGD): Safeguarding Genetic Health

Preimplantation genetic diagnosis (PGD) is a specialized procedure used in conjunction with in vitro fertilization (IVF) to screen embryos for genetic abnormalities before they are implanted in the uterus. This technique allows couples with a history of genetic disorders or chromosomal abnormalities to reduce the risk of passing these conditions on to their offspring. PGD involves the biopsy of one or more cells from a developing embryo, typically on the third or fifth day after fertilization, followed by genetic analysis to detect specific mutations or chromosomal abnormalities. Only embryos that are free of genetic defects are selected for implantation, increasing the likelihood of a healthy pregnancy and reducing the risk of genetic diseases. PGD is particularly valuable for couples who are carriers of hereditary conditions such as cystic fibrosis, Huntington's disease, or sickle cell anemia, as it provides an additional layer of assurance in the reproductive process.

How Are Technological Advancements Enhancing Preimplantation Genetic Diagnosis (PGD)?

Technological advancements have significantly improved the accuracy, reliability, and scope of preimplantation genetic diagnosis (PGD). The advent of next-generation sequencing (NGS) has revolutionized PGD by allowing comprehensive analysis of the entire genome, enabling the detection of a broader range of genetic abnormalities with greater precision. This technology has also reduced the time required for genetic analysis, allowing for faster decision-making in the IVF process. The development of more sophisticated biopsy techniques, such as trophectoderm biopsy on day five embryos, has increased the safety and effectiveness of PGD, minimizing the risk of harm to the embryo while providing a larger and more representative sample for analysis. Additionally, advances in bioinformatics and data analysis have enhanced the interpretation of genetic data, providing more accurate and detailed insights into the genetic health of embryos. These technological improvements have expanded the applications of PGD, making it a more powerful tool for ensuring the genetic health of future generations.

What Are the Key Applications and Benefits of Preimplantation Genetic Diagnosis (PGD)?

Preimplantation genetic diagnosis (PGD) is used in various reproductive scenarios, offering numerous benefits that enhance the likelihood of a healthy pregnancy and reduce the risk of genetic disorders. In cases where one or both parents are carriers of a known genetic mutation, PGD allows for the selection of embryos that do not carry the mutation, significantly reducing the risk of passing the condition on to the child. PGD is also used in cases of recurrent pregnancy loss, where it helps identify embryos with chromosomal abnormalities that are less likely to result in a successful pregnancy. Additionally, PGD is valuable for older women undergoing IVF, as it can screen for age-related chromosomal abnormalities, such as Down syndrome, improving the chances of a healthy pregnancy. The primary benefits of PGD include its ability to reduce the risk of genetic diseases, increase the success rate of IVF, and provide peace of mind to prospective parents. By allowing for the selection of genetically healthy embryos, PGD enhances the reproductive process and contributes to the long-term health of future generations.

What Factors Are Driving the Growth in the Preimplantation Genetic Diagnosis (PGD) Market?

The growth in the preimplantation genetic diagnosis (PGD) market is driven by several factors. The increasing prevalence of genetic disorders and the growing awareness of the benefits of genetic screening in reproductive health are significant drivers. Technological advancements that improve the accuracy, safety, and accessibility of PGD are also propelling market growth. The rising demand for IVF procedures, particularly among older women and couples with a history of genetic disorders, is further boosting the adoption of PGD. Additionally, the expansion of genetic counseling services, which guide couples through the PGD process, is contributing to market growth. The increasing availability of advanced genetic testing technologies and the growing focus on personalized medicine are further driving the market. These factors, combined with the continuous innovation in reproductive genetics, are driving the sustained growth of the PGD market.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Preimplantation Genetic Diagnosis (PGD) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Genetic Disease Prevention Drives Market Growth
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Reproductive Health and Genetic Disorders Expands Addressable Market
    • Growing Adoption of In-vitro Fertilization (IVF) Techniques Throws the Spotlight on PGD
    • Focus on Reducing Risk of Genetic Disorders Enhances Market Prospects
    • Increasing Number of Fertility Clinics and Genetic Counseling Centers Boosts Market Reach
    • Expansion of Personalized Medicine and Precision Healthcare Sustains Market Growth
    • Rising Demand for Gender Selection and Family Balancing Accelerates Market Dynamics
    • Growing Awareness of Late Maternal Age and Associated Risks Spurs Market Demand
    • Collaborations between Research Institutes and Healthcare Providers Generate Innovation
    • Advancements in Genomic Technologies and Bioinformatics Propel Market Expansion
    • Focus on Ethical and Regulatory Compliance Enhances Market Opportunities
    • Increasing Healthcare Expenditure and Insurance Coverage Expands Market Reach
    • Rising Number of Fertility Treatments and Success Rates Boost Market Prospects
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Chromosomal Abnormalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Chromosomal Abnormalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Aneuploidy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Aneuploidy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for X-linked Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for X-linked Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Single Gene Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HLA Typing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for HLA Typing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Gender selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Gender selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other PGD Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 16: World 7-Year Perspective for Other PGD Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 17: World Preimplantation Genetic Diagnosis (PGD) Market Analysis of Annual Sales in US$ for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • JAPAN
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Japan 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • CHINA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 25: China 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • EUROPE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • FRANCE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 31: France 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • GERMANY
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Italy 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • UNITED KINGDOM
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 37: UK 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Spain 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Russia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • AUSTRALIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Australia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • INDIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: India 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 53: South Korea 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • LATIN AMERICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 57: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Argentina 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Brazil 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Mexico 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • MIDDLE EAST
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 69: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Iran 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Israel 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UAE 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • AFRICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Africa 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030

IV. COMPETITION